Trial Profile
A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-445/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Vertex Pharmaceuticals
- 05 Feb 2024 Results presented in a Vertex Pharmaceuticals Media Release.
- 18 May 2022 Results by deriving clinical efficacy inputs were derived from NCT03691779, NCT03525444; estimating survival in Brazilian F/MF pwCF aged 6 years receiving ELX/TEZ/IVA+best supportive care (BSC) versus BSC-alone, presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 20 Apr 2022 According to a Vertex Pharmaceuticals media release, the Larry C. Lands is trial investigator in trial.